{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:35:18Z","timestamp":1790400918130,"version":"4.1.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004417","name":"Global Fund to Fight AIDS, Tuberculosis and Malaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Tanzania rolled-out a 12-dose, weekly regimen of isoniazid plus rifapentine (3HP) TB preventive treatment in January 2024. The 3HP completion rate is generally \u226580%, varying by delivery strategy and programmatic setting. Before the roll-out, a mixed methods study was conducted to assess whether a family approach involving family member support, SMS reminders, and three health education sessions was acceptable and optimized 3HP uptake and completion. This paper describes acceptability of the family approach among people living with HIV (PLHIV), treatment supporters (TS), and community health workers (CHWs). This was a qualitative descriptive study in 12 HIV care and treatment centers across six administrative regions. We purposively sampled 20 PLHIV, 12 CHWs for in-depth interviews, and 23 TS for three focus group discussions held between September and December 2023. The theoretical framework of acceptability guided thematic-content analysis using a framework approach. Participants understood that PLHIV have an increased risk for active TB and that 3HP provides shortened treatment for TB disease prevention. They learned about TB and 3HP through health education sessions, but participation of TS was low due to expensive transportation costs to clinics. Receiving support from a trusted person and SMS were perceived as good adherence reminders. The majority reported mild self-limiting side effects but expressed positive attitudes because of the shortened treatment, TB counseling, satisfaction from helping others, lifestyle and work alignment, and reduced work burden. Some PLHIV had difficulties identifying supportive family members, so they chose close friends or CHWs. The family approach to supporting 3HP adherence is widely accepted by PLHIVs, TS, and CHWs in the context of person-centered care that respects their preferences. We recommend its adoption in programmatic settings as a combined approach, considering changes made during the study. However, further research is warranted to assess its acceptance among other populations eligible for 3HP.<\/jats:p>","DOI":"10.1371\/journal.pgph.0003142","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T13:32:22Z","timestamp":1734442342000},"page":"e0003142","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimizing delivery strategies for 3HP TB preventive treatment in Tanzania: A qualitative study on acceptability of family approach in HIV care and treatment centers"],"prefix":"10.1371","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-5682","authenticated-orcid":true,"given":"Doreen","family":"Pamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-545X","authenticated-orcid":true,"given":"Erica","family":"Sanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7701-1830","authenticated-orcid":true,"given":"Killian","family":"Mlalama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-0628","authenticated-orcid":true,"given":"Lucas","family":"Maganga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chacha","family":"Mangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8011-6948","authenticated-orcid":true,"given":"Anange","family":"Lwilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-6805","authenticated-orcid":true,"given":"Willyhelmina","family":"Olomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Tina","family":"Minja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-6572","authenticated-orcid":true,"given":"Issa","family":"Sabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-6987","authenticated-orcid":true,"given":"Riziki","family":"Kisonga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Matechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaya","family":"Jelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Neema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anath","family":"Rwebembera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyanda Elias","family":"Ntinginya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"pgph.0003142.ref001","author":"World Health Organization","year":"2022","journal-title":"Global Tuberculosis report 2022."},{"key":"pgph.0003142.ref002","author":"Joint United Nations Programme on HIV\/AIDS","year":"2023","journal-title":"The path that ends AIDS: UNAIDS GLOBAL AIDS UPDATE"},{"key":"pgph.0003142.ref003","author":"UNAIDS","year":"2022","journal-title":"FACTSHEET-WORLD TUBERCULOSIS DAY 2022."},{"key":"pgph.0003142.ref004","author":"World Health Organization","year":"2023","journal-title":"Global tuberculosis report 2023."},{"key":"pgph.0003142.ref005","volume-title":"WHO consolidated guidelines on tuberculosis.","author":"World Health Organization","year":"2020"},{"key":"pgph.0003142.ref006","author":"Stop TB Partnership","year":"2018","journal-title":"UNHLM on TB Key Targets & Commitments for 2022."},{"key":"pgph.0003142.ref007","first-page":"16","article-title":"Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania.","author":"WM Maokola","year":"2021","journal-title":"PLoS One"},{"key":"pgph.0003142.ref008","author":"MINISTRY OF HEALTH CDGEAC","year":"2019","journal-title":"NATIONAL GUIDELINES FOR THE MANAGEMENT OF HIV AND AIDS"},{"issue":"2","key":"pgph.0003142.ref009","first-page":"274,923,575.00","article-title":"The United Republic of Tanzania.","volume":"7","author":"MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER EAC.","year":"2019","journal-title":"Development"},{"key":"pgph.0003142.ref010","first-page":"2020","volume":"VI","author":"National Tuberculosis and Leprosy Programme","year":"2023","journal-title":"Report of the Tanzania Mid-Term Review of the National Tuberculosis and Leprosy Programme Strategic Plan"},{"key":"pgph.0003142.ref011","first-page":"18","article-title":"Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.","author":"M Yanes-Lane","year":"2021","journal-title":"PLoS Med"},{"key":"pgph.0003142.ref012","article-title":"Efficacy and Safety of Different Drug Regimens for Tuberculosis Preventive Treatment: A Systematic Review and Meta-Analysis.","author":"R Shah","year":"2023","journal-title":"Cureus"},{"key":"pgph.0003142.ref013","first-page":"20","article-title":"Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: An implementation study.","author":"CK Lam","year":"2018","journal-title":"J Med Internet Res"},{"key":"pgph.0003142.ref014","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1060028019888855","article-title":"Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection","volume":"54","author":"RE Walker","year":"2020","journal-title":"Annals of Pharmacotherapy"},{"key":"pgph.0003142.ref015","first-page":"18","article-title":"Completion of isoniazid\u2013rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness\u2013implementation randomized trial.","author":"FC Semitala","year":"2021","journal-title":"PLoS Med"},{"key":"pgph.0003142.ref016","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection","volume":"167","author":"R Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"pgph.0003142.ref017","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dky403","article-title":"Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: A decision analysis study","volume":"74","author":"TN Doan","year":"2019","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"pgph.0003142.ref018","first-page":"2020","year":"2020","journal-title":"Ministry of Health. NATIONAL TUBERCULOSIS AND LEPROSY STRATEGIC PLAN VI"},{"key":"pgph.0003142.ref019","first-page":"17","article-title":"Acceptability of healthcare interventions: An overview of reviews and development of a theoretical framework.","author":"M Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"pgph.0003142.ref020","first-page":"2","article-title":"Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda\u2014patient and health worker perspectives.","author":"FC Semitala","year":"2021","journal-title":"Implement Sci Commun"},{"key":"pgph.0003142.ref021","doi-asserted-by":"crossref","first-page":"26105","DOI":"10.1002\/jia2.26105","article-title":"Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe\u2019s Fast Track HIV treatment model: experiences from a pilot study","volume":"26","author":"MP Mapingure","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"pgph.0003142.ref022","author":"World Health Organization","year":"2015","journal-title":"DIGITAL HEALTH FOR END TB STRATEGY: AN AGENDA FOR ACTION"},{"key":"pgph.0003142.ref023","first-page":"159","article-title":"Digital health use in latent tuberculosis infection care: A systematic review.","author":"YJ Wong","year":"2022","journal-title":"Int J Med Inform"},{"key":"pgph.0003142.ref024","doi-asserted-by":"crossref","first-page":"e1004356","DOI":"10.1371\/journal.pmed.1004356","article-title":"Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.","volume":"21","author":"FC Semitala","year":"2024","journal-title":"PLoS Med"},{"key":"pgph.0003142.ref025","author":"National AIDS Control Programme","year":"2019","journal-title":"NATIONAL GUIDELINES FOR THE MANAGEMENT OF HIV AND AIDS"},{"key":"pgph.0003142.ref026","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4236\/jtr.2018.62011","article-title":"Family-Based Tuberculosis Counseling Supports Directly Observed Therapy in Armenia: A Pilot Project.","volume":"06","author":"N Truzyan","year":"2018","journal-title":"J Tuberc Res"},{"key":"pgph.0003142.ref027","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-05354-3","article-title":"The effects of family, society and national policy support on treatment adherence among newly diagnosed tuberculosis patients: A cross-sectional study","volume":"20","author":"X Chen","year":"2020","journal-title":"BMC Infect Dis"},{"key":"pgph.0003142.ref028","first-page":"15","article-title":"Tuberculosis Family Support Training\u2019s (TB FaST) Influence on Encouraging TB Treatment Compliance.","author":"H Mariani","year":"2022","journal-title":"Open Public Health J"},{"key":"pgph.0003142.ref029","author":"World Health Organization","year":"2015","journal-title":"WHO End TB Strategy"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T13:32:30Z","timestamp":1734442350000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0003142"}},"subtitle":[],"editor":[{"given":"Julia","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0003142","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}